ipi

528 views

Published on

indian pharma industry

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
528
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
24
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

ipi

  1. 1. HISTORY The Pharmaceutical industry in India is the world's third-largest in terms of volume. According to Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, the total turnover of India's pharmaceuticals industry between 2008 and September 2013 was US$21.04 billion. While the domestic market was worth US$12.26 billion.
  2. 2. CONTD... According to Brand India Equity Foundation, the Indian pharmaceutical market is likely to grow at a compound annual growth rate (CAGR) of 14-17 per cent in between 2012-16. Exports of pharmaceuticals products from India increased from US$6.67 billion in 2011–12 to US$9.7 billion in 2012–13 a combined annual growth rate of
  3. 3. CURRENT SCENARIO Currently, the pharmaceutical industry is also undergoing unprecedented changes. The introduction of product patent regime in 2005 has led to the return of pharmaceutical multinationals to India. The Indian pharma industry is now focusing on drugs developed in-house, contract research, contract production, and particularly in the conduct of clinical trials
  4. 4. CONTD...  The lifestyle drug segment will fuel the growth of India's pharmaceutical industry which includes antidiabetics, antiulcer, antidepressants, cardiovascular, antihypertensive, and drugs needed for Alzheimer's disease, osteoarthritis, cancer, etc.  Currently, the Indian industries are facing tough competition from domestic generic markets and other low-cost drug producing countries, particularly Israel, China, Korea, and those from East Europe.  India has the potential to become the region's hub for pharmaceutical and biotechnological discovery research, manufacturing, exporting, and healthcare services within the next decade.
  5. 5. TURNOVER IN PHARMACEUTICAL INDUSTRY Employee turnover can be disruptive, expensive and affect team morale. Employees leave for many reasons ,such asexciting work and challenges career growth, learning and development working with great people fair pay supportive management/good boss
  6. 6. CONTD...  benefits  great work environment and culture  creativity  flexibility  location  job security and stability  fun on the job  being part of a team  responsibility  inspiring leadership
  7. 7. TOP 10 PHARMACEUTICAL COMPANY  Ranbaxy Labs With total net sales of Rs 7686.59 crore, Ranbaxy is the largest pharmaceutical company in India.  Cipla With total net sales of Rs 6,977.50 crore Cipla is the second largest pharmaceutical company in India.  Dr Reddys Labs With total net sales of Rs 6,686.30 crore Dr Reddys Labs is the third largest pharmaceutical company in India.  Lupin Lupin is the fourth largest pharma company in India with the total net sales of Rs 5,364.37 crore.  Aurobindo Pharma Aurobindo Pharma is on 5th position with the total net sales of Rs 4,284.63 crore.
  8. 8. CONTD...  Sun Pharma Net Sales revenues stood at Rs 4,015.56 crore makes it the sixth largest pharmaceutical company in India.  Cadila Health Cadila Health is the seventh largest pharma company with the total sales revenue of Rs 3,152.20 crore.  Jubilant Life Eight largest company has the total sale revenue at Rs 2,641.07 crore.  Wockhardt Wockhardt has the total net sales of 2,560.16 crore and the ninth largest pharmaceutical company in India.  Ipca Laboratories Revenue of Rs 2,352.59 crore makes Ipca India's 10th largest pharma firm by sales.
  9. 9. CHALLENGES Even after the increased investment, market leaders such as Ranbaxy and Dr. Reddy’s Laboratories spent only 5–10% of their revenues on R&D.  lagging behind Western pharmaceuticals like Pfizer, whose research budget last year was greater than the combined revenues of the entire Indian pharmaceutical industry.
  10. 10. CONTD...  Today, leading domestic pharma companies are global in nature. They have completely diversified their portfolio whereby India does not contribute more than 30 per cent of revenues. They are trying to build a global franchise.  Among the main challenges, new product approvals contributed 4-5 per cent of India’s growth and that has completely disappeared due to the changing regulatory requirements.
  11. 11. GOVT. SUPPORT The Indian government has been very supportive. It established the Department of Biotechnology in 1986 under the Ministry of Science and Technology. Since then, there have been a number of dispensations offered by both the central government and various states to encourage the growth of the industry.
  12. 12. CONTD...  India’s science minister launched a program that provides tax incentives and grants for biotech start-ups and firms seeking to expand and establishes the Biotechnology Parks Society of India to support ten biotech parks by 2015.  The government has also taken steps to encourage foreign investment in its pharma sector. An initiative passed earlier this year allowed 100% foreign direct investment without compulsory licensing from the government.

×